GHRS

GH Research PLC

$15.03

2.31

(18.16%)

Exchange:	NASDAQ
Market Cap:	932.282M
Shares Outstanding:	70M

Overview

Earnings

Financials

Valuation

Chart

About The Company

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

Click to read more…

Revenue Segmentation

Error loading revenue segmentation data: No data found for the specified symbol.

Error loading geo segmentation data: No data found for the specified symbol.

EPS

View full analyst estimates

Earnings Call

No transcript or summary available for this symbol.

Income Statement

Balance Sheet

Cash Flow Statement

Analyst Estimates

Income Statement

(* All numbers are in thousands)

	2019	2020	2021	2022	2023
? Revenue	0	0	0	0	0
? Cost Of Revenue	0	0	19	47	315
? Gross Profit	0	0	-19	-47	-315
? Research And Development Expenses	296	338	8,553	20,484	29,786
? General And Administrative Expenses	14	108	6,547	10,070	11,301
? Selling And Marketing Expenses	0	0	0	0	11,108.699
? Operating Expenses	310	446	15,100	30,554	40,906
? Net Interest Income	0	0	0	0	0
? Interest Income	0	0	9	858	1,890
? Interest Expense	0	0	9	-8,098	723
? Depreciation And Amortization	310	446	19	47	315
? EBITDA	-310	-445	-15,081	-37,730	-40,906
? EBIT
? Operating Income	-310	-446	-15,100	-30,554	-41,221
? Income Before Tax	-310	-446	-9,202	-22,456	-35,587
? Income Tax Expense	-310	-205.297	9	-15,321	-1
? Net Income From Continuing Operations
? Net Income	-310	-446	-9,211	-7,135	-35,587
? EPS (Earnings Per Share)	0	-0.010	-0.180	-0.140	-0.680
? EPS Diluted	0	-0.010	-0.180	-0.140	-0.680
? Weighted Average Shares Outstanding	70,000	70,000	52,020.849	52,020.849	52,022.588
? Weighted Average Shares Outstanding Diluted	70,000	70,000	52,020.849	52,020.849	52,022.588
	USD	USD	USD	USD	USD

Balance Sheet

(* All numbers are in thousands)

	2019	2020	2021	2022	2023
? Cash And Cash Equivalents	498	5,895	276,776	165,955	78,420
? Short Term Investments	0	0	0	0	83,140
? Cash And Short Term Investments	498	5,895	276,776	165,955	161,560
? Net Receivables	0	6	48	90	178
? Accounts Receivables
? Inventory	0	-6	3,008	-90	-178
? Total Current Assets	504	5,912	279,842	168,541	164,089
? Property Plant Equipment Net	0	0	82	97	1,069
? Goodwill	0	0	0	0	0
? Intangible Assets	0	0	0	0	0
? Long Term Investments	0	0	0	85,724	61,142
? Total Non Current Assets	0	0	82	85,821	62,211
? Total Assets	504	5,912	279,924	254,362	226,300
? Account Payables	93	1	883	1,868	3,490
? Short Term Debt	0	0	0	0	343
? Deferred Revenue	0	0	0	0	-3,490
? Total Current Liabilities	104	246	2,749	4,546	6,701
? Long Term Debt	0	0	0	0	631
? Deferred Revenue Non Current	0	0	0	0	0
? Deferred Tax Liabilities Non Current	0	0	0	0	0
? Total Non Current Liabilities	0	0	0	1,868	631
? Total Liabilities	104	246	2,749	4,546	6,701
? Treasury Stock
? Preferred Stock	0	70	0	0	3,350
? Common Stock	801	871	1,301	1,301	1,301
? Retained Earnings	-389	-835	-10,037	-32,493	-67,940
? Additional Paid In Capital
? Total Stockholders Equity	400	5,666	277,175	249,816	218,968
? Total Equity	400	5,666	277,175	249,816	218,968
? Minority Interest	0	0	0	0	0
? Total Liabilities And Total Equity	504	5,912	279,924	254,362	226,300
? Total Investments	0	0	0	85,724	144,282
? Total Debt	0	0	0	0	343
? Net Debt	-498	-5,895	-276,776	-165,955	-78,077
	USD	USD	USD	USD	USD

Cash Flow Statement

(* All numbers are in thousands)

	2019	2020	2021	2022	2023
? Net Income	-310	-1,149	-9,202	-22,456	-35,587
? Depreciation And Amortization	0	1	19	47	315
? Deferred Income Tax	0	0	-5,916	0	6,255
? Stock Based Compensation	0	0	366	1,671	2,291
? Change In Working Capital	21	61	-559	2,159	1,645
? Accounts Receivables	0	0	0	0	0
? Inventory	0	0	0	0	0
? Accounts Payables	0	0	0	0	0
? Net Cash Provided By Operating Activities	-289	-1,087	-15,283	-26,199	-33,336
? Investments In Property Plant And Equipment	0	-21	-104	-67	-100
? Acquisitions Net	0	0	0	0	0
? Purchases Of Investments	0	0	0	-84,621	-54,000
? Sales Maturities Of Investments	0	0	0	0	0
? Net Cash Provided By Investing Activities	0	0	0	0	0
? Net Debt Issuance	0	0	0	0	0
? Long Term Net Debt Issuance	0	0	0	0	0
? Short Term Net Debt Issuance	0	0	0	0	0
? Net Stock Issuance	0	0	0	0	0
? Net Dividends Paid	0	0	0	0	0
? Common Dividends Paid
? Preferred Dividends Paid	0	0	0	0	0
? Net Cash Provided By Financing Activities	797	5,500	286,447	0	-204
? Effect Of Forex Changes On Cash	-10	-211	-179	66	105
? Net Change In Cash	498	-1,319	270,881	-110,821	-87,535
? Cash At End Of Period	498	4,576	276,776	165,955	78,420
? Cash At Beginning Of Period	0	5,895	5,895	276,776	165,955
? Operating Cash Flow	-289	-1,087	-15,283	-26,199	-33,336
? Capital Expenditure	0	-21	-104	-67	-100
? Free Cash Flow	-289	-1,108	-15,387	-26,266	-33,436
	USD	USD	USD	USD	USD

Analyst Estimates

(* All numbers are in thousands)

Fiscal Year	2024	2025	2026	2027	2028
Estimated Revenue (Low)	0	0	0	50,650	118,266.667
Estimated Revenue (High)	0	0	0	50,650	118,266.667
Estimated Revenue (Avg)	0	0	0	50,650	118,266.667
Estimated Ebitda (Low)	0	0	0	0	0
Estimated Ebitda (High)	0	0	0	0	0
Estimated Ebitda (Avg)	0	0	0	0	0
Estimated Net Income (Low)	-48,440.833	-77,513.657	-86,877.723	-67,802.600	-106,993.298
Estimated Net Income (High)	-38,649.662	-44,739.426	-56,184.396	-67,802.600	-106,993.298
Estimated Net Income (Avg)	-43,803.019	-75,260	-71,531.060	-67,802.600	-106,993.298
Estimated SGA Expense (Low)	0	0	0	0	0
Estimated SGA Expense (High)	0	0	0	0	0
Estimated SGA Expense (Avg)	0	0	0	0	0
Estimated EPS (Avg)	-0.840	-1.220	-1.360	-1.300	-2.060
Estimated EPS (High)	-0.740	-0.860	-1.080	-1.300	-2.060
Estimated EPS (Low)	-0.930	-1.490	-1.670	-1.300	-2.060
Number of Analysts (Estimated Revenue)	5	5	3	2	0
Number of Analysts (Estimated EPS)	3	3	3	1	1

Subscribe

Log in

Current Key Metrics

?	Revenue (TTM) :	0	?	P/S (TTM) :	0
?	Net Income (TTM) :	-35587000	?	P/E (TTM) :	-17.14
?	Enterprise Value (TTM) :	527.334M	?	EV/FCF (TTM) :	-12.77
?	Dividend Yield (TTM) :	0	?	Payout Ratio (TTM) :	0
?	ROE (TTM) :	-0.19	?	ROIC (TTM) :	-0.17
?	Net Debt (TTM) :	-149304000	?	Debt/Equity (TTM) :	0
?	P/B (TTM) :	2.33	?	Current Ratio (TTM) :	29.71